In conclusion, our evaluation of the Lumipulse G pTau217 plasma assay demonstrates high accuracy for detecting AD pathology in symptomatic individuals and exclusion of AD pathology in asymptomatic persons, and a strong correlation with tau PET that assists staging of AD, on a widely available platform that will facilitate clinical implementation. This evidence concerns the gene MAPT and Alzheimer disease.